hmr 1766 has been researched along with ramipril in 1 studies
| Studies (hmr 1766) | Trials (hmr 1766) | Recent Studies (post-2010) (hmr 1766) | Studies (ramipril) | Trials (ramipril) | Recent Studies (post-2010) (ramipril) |
|---|---|---|---|---|---|
| 23 | 1 | 11 | 2,151 | 606 | 509 |
| Protein | Taxonomy | hmr 1766 (IC50) | ramipril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.004 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauersachs, J; Fraccarollo, D; Galuppo, P; Motschenbacher, S; Ruetten, H; Schäfer, A | 1 |
1 other study(ies) available for hmr 1766 and ramipril
| Article | Year |
|---|---|
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Cell Communication; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Enzyme Activators; Extracellular Matrix; Fibrosis; Guanylate Cyclase; Heart Failure; Hemodynamics; Humans; Male; Mice; Mitochondria, Heart; Myocardial Contraction; Myocardial Infarction; Myocytes, Cardiac; Myofibroblasts; Nitric Oxide; Nitric Oxide Synthase Type III; ortho-Aminobenzoates; Oxidative Stress; Ramipril; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |